Production and Evaluation of an Antimicrobial Peptide-Containing Wafer Formulation for Topical Application
- 792 Downloads
A targeted approach for direct topical antimicrobial delivery involving the formulation of impregnated freeze-dried wafers prepared from a natural polymer has been assessed to consider potential for treatment of wounded skin. The synthetic cationic antimicrobial peptides (CAPs) NP101 and NP108 were found to have modest in vitro activity against bacterial species commonly associated with wound infections. Minimum inhibitory concentration/minimum bactericidal concentrations against Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa were found to be 0.31 mg/ml for NP101 and 0.25–0.5 mg/ml for NP108. Rapid, substantial cytoplasmic potassium loss was induced by NP108 in E. coli, but not the other species. Through scanning electron microscopy, both CAPs were observed to alter cell morphology, prevent normal septation, promote cell aggregation and trigger release or formation of extracellular filaments. Wafers harbouring these agents displayed substantial antibacterial activity when assessed by standard diffusion assay. These data confirm that topical delivery of CAPs, through their incorporation within freeze-dried wafer formulations prepared from natural polymers, represents a potential viable approach for treating skin infection.
KeywordsChronic Wound Topical Delivery Intracellular Potassium Potassium Loss Cationic Antimicrobial Peptide
The authors would like to thank Emily Hunter and Iain Tough for assistance with operation of the SEM and Dr Tim King for valuable assistance with interpretation of SEM images. The work was supported in part by an award (G08/10) to KHM by Tenovus Scotland. The authors declare that they have no conflict of interest.
- 5.Chua K, Laurent F, Coombs G, Grayson ML, Howden BP (2011) Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 52:99–114. doi: 10.1093/cid/ciq067 PubMedCrossRefGoogle Scholar
- 15.Matthews KH, Stevens HNE, Auffret AD, Humphrey MJ, Eccleston GM (2008) Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant. Int J Pharm 356:110–120. doi: 10.1016/j.ijpharm.2007.12.043 PubMedCrossRefGoogle Scholar
- 16.O’Neil D, Mercer D, Charrier C (2006) Inhibition of biofilm organisms. International Patent A61K 38/04Google Scholar
- 17.Pag U, Oedenkoven M, Sass V, Shai Y, Shamova O, Antcheva N, Tossi A, Sahl HG (2008) Analysis of in vitro activities and models of action of synthetic antimicrobial peptides derived from an alpha-helical ‘sequence template’. J Antimicrob Chemother 61:341–352. doi: 10.1093/jac/dkm479 PubMedCrossRefGoogle Scholar